



October 2019 - Volume 17 - Issue 10  
North American Edition

## Table of Contents

### The Evolution and Feasibility of Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk: A Review

By Aditya Sengupta, MD;  
Sophia L. Alexis, MD;  
Gilbert H. L. Tang, MD, MSc, MBA - p. 1

### A Melody for the Elderly

By Aphrodite Tzifa, MD, FRCPC; Dimosthenis Avramidis, MD; Dimitra Loggitsi, MD, PhD; Konstantinos Spargias, MD, PhD - p. 12

### Medical News, Products & Information - p. 16

Recruitment - p. 3, 5, 6, 10, 13, 15, 17, 20, 21, 23, 24, 25, 26

## Upcoming Medical Meetings

### 12th Annual Master Class in Congenital Cardiac Morphology – UPMC Children's Hospital of Pittsburgh

Oct. 9-11, 2019; Pittsburgh, PA, USA  
[www.chp.edu/masterclassccm](http://www.chp.edu/masterclassccm)

### Living with Cardiomyopathy Family Conference

Oct. 11-12, 2019; Philadelphia, PA, USA  
<http://dev.childrenscardiomyopathy.org/Cardiomyopathy-Family-Conference-77-377>

### 5th Annual Adult Congenital Heart Symposium

Oct. 12, 2019; Houston, TX, USA  
[attend.houstonmethodist.org/event/5th-annual-adult-congenital-heart-symposium#.XUhWbJNKhhF](http://attend.houstonmethodist.org/event/5th-annual-adult-congenital-heart-symposium#.XUhWbJNKhhF)

### AiMed 19

Dec. 11-14, 2019; Dana Point, CA, USA  
[www.aimed.events/north-america-2019](http://www.aimed.events/north-america-2019)

### Corporate Office

11502 Elk Horn Drive  
Clarksburg, MD 20871 USA

 @ccardiology

[www.CongenitalCardiologyToday.com](http://www.CongenitalCardiologyToday.com)

Official publication of the CHiP Network

# The Evolution and Feasibility of Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk: A Review

## TAVR in Low-Risk Patients

By Aditya Sengupta, MD; Sophia L. Alexis, MD; Gilbert H. L. Tang, MD, MSc, MBA

### Introduction

Since its first clinical application in 2002, Transcatheter Aortic Valve Replacement (TAVR) has evolved dramatically and has surpassed Surgical Aortic Valve Replacement (SAVR) as the standard of care for patients with severe symptomatic aortic stenosis who are at an intermediate or higher risk for surgery<sup>1-12</sup>. Trial data now suggest that TAVR with a balloon-expandable or self-expanding transcatheter heart valve (THV) is at least as safe and effective as SAVR in patients at low surgical risk<sup>13-16</sup>. Here, we critically assess the data from the recent low-risk TAVR studies in the context of its evolving clinical indications. Outstanding issues, including long-term adverse events and durability, are also discussed.

### Landmark Low-Risk Trials

Four landmark trials comparing TAVR with SAVR in patients at low surgical risk are discussed below (Table 1).

### Author & Funding Disclosures

Dr. Tang is a physician-proctor for Edwards Lifesciences and Medtronic.

### Abstract

This past decade has witnessed the evolution of Transcatheter Aortic Valve Replacement (TAVR) as the preferred treatment for symptomatic severe aortic stenosis in patients who are at an intermediate, high, or extreme risk for surgery. Four landmark clinical trials now provide strong evidence that TAVR is non-inferior, and perhaps even superior, to surgery at short- and mid-term follow-up. However, issues such as new-onset left bundle branch block and permanent pacemaker implantation continue to plague outcomes after TAVR, and the long-term durability of the implanted bioprostheses have yet to be determined before TAVR can be universally adopted.

## Recruit with CCT

Recruitment advertisements are listed

- In print and electronic monthly issue
- On our website
- In our monthly email blast



Contact: [Kate@cct.bz](mailto:Kate@cct.bz)

**Table 1. Summary & Comparison of Low-Risk TAVR Trials**

Trial (Ref)	Design	Patients (N)	Risk Stratification	Primary Outcome	Key Secondary Outcomes
<b>PARTNER 3</b> <sup>13</sup>	1:1 Randomization, Transfemoral SAPIEN 3 THV vs. SAVR	503 TAVR 497 SAVR	STS-PROM < 4%	Composite of Death, Stroke, or Rehospitalization at 1 Year: 8.5% in TAVR vs. 15.1% in SAVR, Absolute Difference -6.6 Percentage Points, 95% CI -10.8 to 0.2, P < 0.001 for Noninferiority; HR 0.54, P = 0.001 for Superiority	30-Day TAVR vs. SAVR ~ Stroke Rate: 0.6% vs. 2.4%, P = 0.02  Death or Stroke: 1.0% vs. 3.3%, P = 0.01  New-Onset AF: 5.0% vs. 39.5%, P < 0.001
<b>Evolut Low Risk</b> <sup>14</sup>	1:1 Randomization, Medtronic CoreValve/ Evolut R/Evolut PRO THV vs. SAVR	734 TAVR 734 SAVR	STS-PROM < 3%	Composite of Death or Disabling Stroke at 2 Years: 5.3% TAVR vs. 6.7% SAVR, Difference -1.4, Bayesian Credible Interval for Difference, -4.9 to 2.1, Posterior Probability of Noninferiority > 0.999	30-Day TAVR vs. SAVR ~ Disabling Stroke: 0.5% vs. 1.7%; Bleeding Complications: 2.4% vs. 7.5%; AKI 0.9% vs. 2.8%; AF 7.7% vs. 35.4%; Moderate/ Severe AR 3.5% vs. 0.5%, PPM 17.4% vs. 6.1%
<b>MedStar Low Risk TAVR</b> <sup>33</sup>	Prospective, Multicenter Feasibility Trial, Transfemoral SAPIEN 3 or CoreValve Evolut R THV vs. SAVR	200 TAVR vs. 200 Historical Propensity-Score Matched, Site-Specific Isolated SAVR Patients (from STS Database)	STS-PROM < 3%	Zero All-Cause Mortality at 30 Days	30 Days: 0 Disabling Stroke, 5.0% PPM, and 14.0% HALT; 1 Year: 3.0% Mortality, 2.1% Stroke, 7.3% PPM; Valve hemodynamics were not impacted by HALT
<b>NOTION (6-Year Outcomes)</b> <sup>36</sup>	1:1 Randomization, Medtronic 1 <sup>st</sup> Generation CoreValve THV vs. SAVR	139 TAVR vs. 135 SAVR Randomized; 6-Year Follow-Up: 50 TAVR vs. 50 SAVR	TAVR vs. SAVR, Mean STS-PROM: 3.0 ± 1.7% vs. 3.0 ± 1.6%	6-Year All-Cause Mortality, TAVR vs. SAVR: 42.5% vs. 37.7% (P = 0.58)	6-Year SVD, TAVR vs. SAVR: 24.0% vs. 4.8% (P < 0.001); Endocarditis: 5.9% vs. 5.8% (P = 0.95); BVF: 6.7% vs. 7.5% (P = 0.89)

The results of four landmark low-risk trials are summarized here. AF = Atrial Fibrillation; AKI = Acute Kidney Injury; AR = Aortic Regurgitation; BVF = Bioprosthetic Valve Failure; CI = Confidence Interval; HALT = Hypoattenuated Leaflet Thickening; HR = Hazard Ratio; NORDIC = Nordic Aortic Valve Intervention; PARTNER = Placement of Aortic Transcatheter Valves; PPM = Permanent Pacemaker; SAVR = Surgical Aortic Valve Replacement; STS-PROM = Society of Thoracic Surgeons-Predicted Risk of Mortality; SVD = Structural Valve Deterioration; TAVR = Transcatheter Aortic Valve Replacement; THV = Transcatheter Heart Valve.

**The PARTNER 3 & Evolut Low-Risk Trials**

The Placement of Aortic Transcatheter Valves (PARTNER) 3 Trial evaluated the noninferiority and superiority of the Edwards SAPIEN 3 THV (N = 503) versus SAVR (N = 497) in low-risk patients (Society of Thoracic Surgeons Risk of Mortality, or STS-PROM, <4%). The composite endpoint of death from any cause, stroke, or re-hospitalization at one year was significantly lower with TAVR. While the vast majority of the 30-day safety end points were similar between the two treatment arms, the rates of new-onset atrial fibrillation (AF) at 30 days, death or stroke at 30 days, and length of hospitalization were significantly lower with TAVR<sup>13</sup>.

Similarly, the Evolut Low-Risk Trial tested the non-inferiority of the Medtronic self-expanding THV (N = 725) against surgery (N = 678) in low-risk patients. Here, three different self-expanding prostheses were used for TAVR due to their availability during the study period (CoreValve, Evolut R, or Evolut PRO). Compared to the PARTNER 3 trial, this study had a longer follow-up period of two years with regards to the composite primary endpoint of death or disabling stroke (5.3% vs. 6.7%, posterior probability > 0.999 for noninferiority). Furthermore, at 30 days, TAVR patients had a lower incidence of AF and life-threatening bleeding, but a higher incidence of at least moderate aortic regurgitation (AR)<sup>14</sup>.

Both trials demonstrated that TAVR is at least as efficacious and safe as SAVR in low-risk patients at 1-2 years. In particular, new permanent pacemaker (PPM) implantation, at least moderate paravalvular leak (PVL), and coronary artery obstruction occurred with equal frequency in both arms of the PARTNER 3 study. This is in contrast to previous trials where the aforementioned complications occurred more frequently with SAVR as compared to TAVR<sup>10,17-24</sup>. Furthermore, both studies showed low rates of aortic valve re-intervention at one year with TAVR (0.6% in PARTNER 3, 0.7% in Evolut). As expected, new left bundle-branch block (LBBB) and mild PVL favored SAVR. Of note, TAVR in the Evolut Trial resulted in a higher incidence of PPM implantation (17.4% at 30 days and 19.4% at one year) than SAPIEN 3 TAVR (6.6% at 30 days and 7.5% at one year); the design differences between a balloon-expandable and self-expanding valve may partly explain this discrepancy.

There were a number of limitations common to both studies, the most obvious of which was the lack of follow-up beyond 12-24 months (note that the recently published FinnValve trial, with follow-up of up to three years, corroborate the aforementioned findings)<sup>25</sup>. Structural valve deterioration (SVD), along with the implications of PVL and patient-prosthesis mismatch, will have to be assessed<sup>26-28</sup>. In particular, the Evolut Trial demonstrated a lower rate of severe patient-prosthesis mismatch at one year in the TAVR group (1.8% vs. 8.2%), albeit larger valve areas; the long-term sequelae of this finding will need to be ascertained, especially since severe patient-prosthesis mismatch occurred less frequently compared to prior studies<sup>29,30</sup>. Furthermore, a stronger selection bias may have occurred in the PARTNER 3 trial since a third of screened patients were excluded for various anatomical reasons. In contrast, this rate was approximately 15% in the Evolut trial<sup>31</sup>.

These results may also not be universally applicable. For one, bicuspid valvulopathy was an exclusion criterion in both studies, whereas bicuspid disease accounts for approximately 50% of all

**We're Hiring**

**Heart Failure  
Pulmonary Hypertension  
Transplant Cardiologist**

Sidra Heart Center at Sidra Medicine is recruiting a cardiologist, at the assistant or associate or full professor level, to join a large academic practice and initiate a new service focusing on heart failure, pulmonary hypertension and heart transplantation. Sidra Heart Center has 11 cardiologists, 7 intensivists, 2 cardiothoracic surgeons, three CTS hospitalists, 5 CICU hospitalists and one nurse practitioner.

Candidates must be board-eligible or certified or equivalent in pediatric cardiology. Candidates who have completed advanced training in heart failure and transplantation with an established academic portfolio or strong academic potential are preferred. The successful candidate will have the opportunity to establish a new program in a brand new academic medical center with adequate resources. The program will be a referral center in Qatar, the gulf and beyond.

Sidra Medicine is the primary pediatric teaching facility and the only dedicated Children's hospital in Qatar. It is the primary teaching hospital for Pediatrics for medical students from Weill Cornell medical College-Qatar. In addition, it serves also as a teaching hospital for students from Qatar University Medical College. Clinical responsibilities for the candidate include out-patient clinics and general pediatric cardiology night/weekend call divided among the group. The CICU gets covered by dedicated cardiac intensivists. There is an active fellowship program as well as an ACGMEi accredited residency program in Pediatrics. Sidra Heart Center clinical metrics: 200 cardiothoracic surgeries, 350-400 cardiac interventional and EP procedures, and over 9000+ cardiology out-patient encounters. The center already participates in clinical trials and is a member of the IMPACT registry from the ACC.

Interested candidates are encouraged to submit their curriculum vitae to: Ziyad M. Hijazi, MD, director of Sidra Heart Center and Executive Chair of Pediatric Medicine at Sidra Medicine (zhijazi@sidra.org)



AVRs<sup>32</sup>. The vast majority of patients had ejection fractions (EF) >60%, none had severe multi-valvular disease, and women were a minority in both studies (28.9% to 36.2%). Nevertheless, the outcomes from both trials constitute the next step forward in the evolution of TAVR and represent a monumental advance in the treatment of Severe Symptomatic Aortic Stenosis.

#### Low-Risk TAVR (LRT) Trial

The LRT trial prospectively compared TAVR (N = 200) in low-risk patients (STS-PROM 1.8 ± 0.5%) to a historical control cohort of SAVR patients from the STS database<sup>16</sup>. No patients reached the primary endpoint of all-cause mortality at 30 days. At one year, mortality, stroke, and PPM implantation rates were 3.0%, 2.1%, and 7.3%, respectively. Greater than mild PVL was seen in 1.5%. The improvements in aortic valve area (AVA) and mean gradient (MG) seen at 30 days persisted to one year<sup>33</sup>.

In addition to validating the outcomes of the PARTNER 3 and Evolut trials, the LRT study provides a degree of generalizability to low-risk TAVR patients in the United States<sup>10, 11, 34</sup>. Moreover, the LRT study had remarkably low stroke rates at one year.

However, this was not a randomized study, and data are limited to a 12-month period. Interestingly, there was a relatively high rate of leaflet thrombosis post-TAVR, a finding that was comparable to data from the SAVORY (Subclinical Aortic Valve Bioprosthesis Thrombosis Assessed with Four-Dimensional Computed Tomography) and RESOLVE (Assessment of Transcatheter and Surgical Aortic Bioprosthetic Valve Thrombosis and Its Treatment with Anticoagulation) observational registries<sup>35</sup>. This is discussed in greater detail below.

#### Nordic Aortic Valve Intervention (NOTION) Trial

The NOTION Trial was the first randomized study that compared TAVR with the CoreValve bioprosthesis to trial SAVR in low-risk patients (STS-PROM 3.0 ± 1.7%)<sup>15</sup>. At six years, there was no difference in all-cause mortality. The MG was lower and the effective orifice area (EOA) was larger after TAVR; these differences persisted through all six years of follow-up (p < 0.001). SVD was significantly higher in the SAVR arm mainly due to higher post-procedure MGs, but there were no differences in bioprosthetic valve failure (BVF) rates<sup>36</sup>.

Even though the outcomes of the NOTION Trial were favorable and comparable to previous high- and intermediate-risk studies, a number of key limitations deserve special attention<sup>37</sup>. First, the indications for new PPM implantation were not entirely clear; coupled with the use of an older generation, non-repositionable self-expanding valve and older deployment techniques, this may partially explain the unusually high rate of PPM implantation (43.7% post-TAVR vs. 8.7% post-SAVR at 5-years, p < 0.001)<sup>38</sup>. The implications of the dramatically higher incidence of SVD post-SAVR are also unclear, and the results have to be interpreted with caution. As Tang et al. point out, a disproportionately greater number of larger valves were used in the TAVR arm since echocardiography (rather than CT) was used for sizing. These larger valves also tend to have lower baseline MGs<sup>39</sup>. Lastly, given that mortality and BVF rates were similar between the two groups (and validated by a lack of clinical differences in the CoreValve US

pivotal trial), there remain unanswered questions regarding the validity of the SVD definition used in this study<sup>37</sup>.

#### Outstanding Issues & Future Directions

Several issues remain that need to be addressed as TAVR is expanded to low-risk patients.

##### Stroke

One of the major shortcomings of TAVR after the original PARTNER Trial was the significantly higher rate of stroke with transcatheter therapy<sup>23</sup>. In the early development of TAVR, this was attributed to inexperienced operators and larger delivery systems. The current stroke rates in high-risk patients are decreasing, and stand in stark contrast to those shown in the low-risk trials<sup>13, 14, 33</sup>. The advent of cerebral protection devices has aided in reducing the stroke risk. For instance, Ndunda et al. performed a meta-analysis in 1,330 patients using the Sentinel Cerebral Protection System (Claret Medical Inc., Santa Rosa, CA, USA) and discovered that it conferred a decrease in clinical stroke at 30 days<sup>40</sup>. In contrast, SAVR stroke rates may never be quite as low given the risks associated with cardiopulmonary bypass, post-operative AF, manipulation of a calcified aorta, and debridement of diseased valves<sup>41</sup>.

##### Paravalvular Leak

Five-year data from the NOTION Trial showed a significant difference in TAVR versus SAVR with mild PVL in 45.9% vs. 16.7% and moderate PVL in 7.1% vs. 0%. The clinical implication of this is still unclear as both groups had similar NYHA functional class and all-cause mortality, even for patients with moderate regurgitation at three months, by the end of the study<sup>43</sup>. One-year results from PARTNER 3 and Evolut showed no significant difference in outcomes in patients with up to mild PVL<sup>13, 14</sup>.

##### Conduction Abnormalities

Conduction abnormalities are a well-known complication of TAVR<sup>44</sup>. For instance, Nazif et al. found a 15.4% rate of LBBB at hospital discharge in 1,179 patients at intermediate risk from the PARTNER II Trial and S3i Registry. These patients had a significantly higher mortality at two years<sup>45</sup>. Currently, prophylactic PPM implantation is not merited since ~ 40% of LBBB resolves at one month.

While the PARTNER 3 Trial did not show a difference in PPM insertions, new LBBB at one year was almost three times as high in the TAVR group<sup>131</sup>. In contrast, there was a higher PPM implantation rate in the Evolut Low Risk Trial, but we do not know how many of these patients remained pacemaker-dependent at one year; the incidence of new LBBB was not reported<sup>13</sup>. The NOTION Trial was able to correlate pacemaker implantation with a difference in mortality of 38.2% versus 21.7% at five years<sup>43</sup>. Though we have not yet solved how to completely avoid this complication, minimizing valve manipulation, avoiding oversizing, and implanting at higher depths can decrease conduction disturbances<sup>46</sup>.



# Pediatric Cardiologist Faculty Position

UC Davis Children's Hospital  
School of Medicine  
Department of Pediatrics  
Pediatric Cardiology

The Department of Pediatrics at the University of California, Davis School of Medicine is recruiting two full-time academic pediatricians within the Pediatric Cardiology specialty. We are recruiting at the Assistant/Associate/Full Professor rank (commensurate with credentials) in the Clinical Pediatrics or Health Sciences Clinical Series in the Division of Pediatric Cardiology.

The candidate's primary clinical duties include: 1) general outpatient pediatric cardiology in our clinic as well as in an outreach setting, 2) inpatient consult service, 3) supervise and interpret pediatric echocardiograms and EKG's. Optional skillsets include ability to perform and interpret fetal echocardiograms, management of cardiomyopathies and heart failure and supervise and interpret cardiopulmonary exercise testing. Work distribution will depend on the specific skillset of the candidate. It is expected that the candidate will share in the on-call and weekend/holiday coverage schedule.

In addition to the clinical responsibilities, the ideal candidate will be expected to participate in teaching of medical students, residents and fellows, research activities of the Department of Pediatrics, and serve on departmental committees. A background and/or interest in research or quality improvement is preferred.

Candidates must have the following experience/qualifications:

- M.D. or D.O.
- Successful completion of an approved pediatric residency training program
- Successful completion of an approved Pediatric Cardiology fellowship training program at this hire
- Board certification/eligibility in Pediatric Cardiology
- Eligibility for a California Medical License
- Ability to foster collegiality and work collaboratively in a diverse environment

The Pediatric Heart Center at UC Davis Children's Hospital is inland Northern California's only full-service cardiac care facility for children and young adults, offering the latest tests and treatments for a range of congenital or acquired cardiovascular conditions. Our integrated multidisciplinary team of surgeons, specialists, physicians, nurses and researchers offer Northern California's most sophisticated specialized diagnostic, interventional and surgical expertise in comprehensive diagnostic, therapeutic, and surgical procedures for children with heart defects.

For full consideration applications should be received by September 18, 2019; however the position will remain open until filled through June 30, 2020. Completed applications include CV, Cover Letter, Statement of Teaching, Statement of Contributions to Diversity, Equity, and Inclusion and contact information for 3-5 references.

Candidates should submit their application online at: <https://recruit.ucdavis.edu/apply/JPF03115>.

With more than 120 physicians in 33 pediatric subspecialties, the Children's Hospital is a 118-bed hospital housed within the 619-bed University of California, Davis Medical Center. It is the only designated Children's Hospital in the Sacramento region, and is known for offering comprehensive, compassionate, family-centered care. UC Davis Children's Hospital is distinguished for its outstanding congenital heart program and its internationally recognized telemedicine programs. Within the last few years, UC Davis Children's Hospital built a new 49-bed Neonatal Intensive Care Unit and a new 24-bed Pediatric Intensive Care Unit/Pediatric Cardiac Intensive Care Unit.

The UC Davis Children's Hospital is based on the UC Davis Health campus in Sacramento, California and serves a population of over 1 million children in the Northern California, Central Valley and Western Nevada regions. Sacramento is an easily accessible, family-oriented city in close proximity to the San Francisco Bay area, Lake Tahoe and the Sierra Nevada Mountains, the California coast, and Napa Valley.

UC Davis commits to inclusion excellence by advancing equity, diversity and inclusion in all that we do. We are an Affirmative Action/Equal Opportunity employer, and particularly encourage applications from members of historically underrepresented racial/ethnic groups, women, individuals with disabilities, veterans, LGBTQ community members, and others who demonstrate the ability to help us achieve our vision of a diverse and inclusive community. For the complete University of California nondiscrimination and affirmative action policy see: <http://policy.ucop.edu/doc/4000376/NondiscrimAffirmAct>. If you need accommodation due to a disability, please contact the recruiting department.

Under Federal law, the University of California may employ only individuals who are legally able to work in the United States as established by providing documents as specified in the Immigration Reform and Control Act of 1986. Certain positions funded by federal contracts or sub-contracts require the selected candidate to pass an E-Verify check. More information is available <http://www.uscis.gov/e-verify>.

UC Davis is a smoke & tobacco-free campus (<http://breathefree.ucdavis.edu/>).

## Coronary Reaccess

Careful consideration of coronary height and aortic root dimensions is paramount when choosing the appropriate THV device. Valve positioning is also key, particularly in younger patients in whom reintervention for progressive CAD is probable. Recent evidence suggests that unlike SAVR, the THV orientation relative to native aortic valve commissures appear random, and in >50% of cases, a THV commissure has overlap with one or both coronaries<sup>47</sup>. Understanding native aortic root anatomy and THV features will facilitate the ability to perform coronary reaccess<sup>48</sup>. In addition, depending on the valve type, the initial THV orientation at deployment may or may not impact the final orientation<sup>49,50</sup>. Tang et al. recently reported that crimping the SAPIEN 3 valve at various orientations relative to the delivery catheter had no significant difference in the incidence of severe neo-commissural overlap with the coronaries<sup>49</sup>. On the other hand, having the “Hat” marker of the Evolut catheter facing the outer curve or center front position during initial deployment significantly reduced severe overlap<sup>50</sup>. Newer THVs such as the JenaValve (JenaValve Inc., Irvine, CA) and J-Valve (JC Medical, China) that require commissural alignment for deployment may make coronary reaccess easier. This issue will be important as TAVR expands to younger and lower-risk patients, or those with moderate CAD that may progress with time.

## Durability

It is well documented that the longevity of bioprosthetic valves is directly proportional to age. In low-risk patients, we do not yet have robust data, but after five years, re-intervention was necessary in 3/145 in the TAVR group (for PVL) and 1/135 in the SAVR group in the NOTION Trial<sup>43</sup>. In contrast, we do have longer-term data in intermediate/high-risk patients. In 8-year data collected from 990 patients in eight Italian centers using CoreValve, reintervention occurred only 13 times at >30 days<sup>51</sup>. In the 19 patients that survived at the Vancouver center that reported 10-year follow-up, there was 89.5% freedom from reintervention with 76.5% freedom from moderate to severe SVD<sup>52</sup>. Valve durability will be an important issue in younger patients, where redo-TAVR may be limited by the initial THV type and root anatomy<sup>49</sup>.

## Subclinical Leaflet Thrombosis

Most patients with subclinical leaflet thrombosis are asymptomatic. Often overlooked, it is likely caused by reduced leaflet motion or blood flow in the neo-sinuses that are surrounded by the native aortic valve leaflets<sup>53</sup>. In the PARTNER 3 and Evolut trials, there was no difference in amount of valve thrombosis at 30 days for TAVR versus SAVR. In the LRT study, 14.0% of patients had subclinical leaflet thrombosis at one month<sup>13,14,33</sup>. Even though there was a trend towards a higher stroke rate in patients with hypoattenuated leaflet thickening, the actual event rates were very low (1 vs. 4 strokes) and the trial was not adequately powered to detect differences<sup>33</sup>.

Interestingly, Chakravarty et al. found an association between subclinical leaflet thrombosis and cerebrovascular events. In their study of 890 patients, 13% of TAVR valves versus 4% of surgical valves had subclinical leaflet thrombosis with resultant increased rates of all strokes or transient ischemic attacks<sup>35</sup>. Fortunately,



## Interventional Cardiologist

Saint Louis University, a Catholic, Jesuit institution dedicated to student learning, research, health care, and service is seeking an additional pediatric cardiologist to join an established group within the Division of Cardiology and the Department of Pediatrics at SSM Health Cardinal Glennon Children's Hospital. Applicants must be board certified/eligible in Pediatric Cardiology. General responsibilities will include clinical care, teaching, and research.

We are seeking a second invasive cardiologist at the Assistant or Associate Professor level to assist our current faculty with the growing number of cardiac catheterizations and interventional cases. The complete spectrum of pediatric interventional procedures is currently being performed. An interest in clinical research is encouraged. Academic rank will be commensurate with qualifications and experience.

The cardiology division is housed within the Dorothy and Larry Dallas Heart Center at SSM Health Cardinal Glennon Children's Hospital. The Heart Center opened in 2009 and underwent significant expansion in 2016. An active congenital heart surgery program exists, and the hospital houses state-of-the-art operating rooms, neonatal intensive care unit, pediatric intensive care unit, electrophysiology lab, and a hybrid cardiac catheterization lab/operating suite. SSM Cardinal Glennon Children's Hospital is a free-standing children's hospital, and is staffed by faculty members of Saint Louis University School of Medicine.

Interested candidates must submit a cover letter, application, and current CV to <http://jobs.slu.edu>.

Other correspondence regarding this position can be sent to: **Kenneth O. Schowengerdt, MD**  
Wieck-Sullivan Professor and Director of Pediatric Cardiology  
Saint Louis University School of Medicine  
1465 South Grand Blvd, St. Louis, MO 63104  
T. 314.577.5633  
F. 314.268.4035  
[kenneth.schowengerdt@health.slu.edu](mailto:kenneth.schowengerdt@health.slu.edu)

*Saint Louis University is an Affirmative Action, Equal Opportunity Employer, and encourages nominations of and applications from women and minorities.*

prevention/resolution was possible with anticoagulation, but the question of when to initiate such therapies to improve hemodynamics remains unanswered.

## Valve Reintervention

For young patients who may need multiple aortic valve interventions, questions remain regarding the feasibility of redo-TAVR and the ability to extract the THV surgically without replacing the aortic root. TAVR-in-SAVR is approved for high- or extreme-risk patients and is a relatively simple procedure, but comes with a higher risk of coronary obstruction<sup>49,54</sup>. In patients with small surgical valves, balloon valve fracture may be feasible in certain bioprostheses<sup>54</sup>. These choices must be weighed carefully, especially since re-operative SAVR is safe with low mortality in low-risk, younger patients<sup>42</sup>. In failing THVs, redo-TAVR has seldom been described. In contrast to TAVR-in-SAVR, the THV stent frame in redo-TAVR is typically higher than surgical valves with an associated higher risk of coronary obstruction. To this end, Tang et al. have devised a classification scheme using angiographic data describing the aortic root anatomy relative to valve positioning and stent frame dimensions to determine the feasibility of redo-TAVR<sup>49</sup>. Furthermore, because THV orientation relative to native commissures tends to be random and the native aortic valve leaflets become barriers to the coronary orifices, leaflet management techniques, such as Bioprosthetic or native Aortic Scallop Intentional Laceration to prevent iatrogenic Coronary Artery obstruction during TAVR (BASILICA), may not adequately reduce coronary obstruction risk in redo-TAVR<sup>55</sup>.

## Endocarditis

Rates of prosthetic valve endocarditis (PVE) after TAVR and SAVR have reportedly been similar, around 1.5% within a year. In 20,006 patients who underwent TAVR, Regueiro et al. discovered a 1.1% incidence per person-year of PVE with mean time to diagnosis of 5.3 months post-implantation. Younger age was a risk factor (although this study took place with a higher risk cohort). Eighty-two percent were treated with antibiotics alone and 14.8% required surgical intervention (10.8% were transcatheter valve explantations)<sup>56</sup>. In another study, based on the FinnValve Registry 6,463 consecutive patients who underwent

TAVR and SAVR were found to have no significant difference in risk (3.4/1,000 person-years vs. 2.9/1,000 person-years) over an 8-year observational time period<sup>57</sup>. Yeo et al. similarly found younger age as an independent risk factor when looking at 41,025 patients with TAVR (OR 0.92, 95% CI 0.89 to 0.95), and so did Kolte et al. in an evaluation of 29,306 TAVR patients. Larger stent posts, groin access, involvement of pacemaker leads (given higher rate of implantation), and decreased sterility outside of a main operating room could be possible reasons<sup>58,59</sup>.

## Conclusion

TAVR is rapidly becoming an appealing option for a younger, low-risk population that may not wish to undergo surgery. Given recent trial data, estimated surgical risk no longer directs the dichotomy between TAVR and SAVR. As this paradigm shifts, issues such as new conduction abnormalities, coronary reaccess, structural valve deterioration and long-term durability all need to be discussed with the patient. Appropriate patient selection based on clinical and anatomic factors is of the utmost importance when considering candidacy for TAVR versus SAVR.

## References

1. Puri R, Chamandi C, Rodriguez-Gabella T, Rodes-Cabau J. Future of transcatheter aortic valve implantation - evolving clinical indications. *Nat Rev Cardiol* 2018;15:57-65.
2. Cribier A, Eltchaninoff H, Bash A et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. *Circulation* 2002;106:3006-8.
3. Baumgartner H, Falk V, Bax JJ et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J* 2017;38:2739-2791.
4. Deeb GM, Reardon MJ, Chetcuti S et al. 3-Year Outcomes in High-Risk Patients Who Underwent Surgical or Transcatheter Aortic Valve Replacement. *J Am Coll Cardiol* 2016;67:2565-74.
5. Kapadia SR, Leon MB, Makkar RR et al. 5-year outcomes of transcatheter aortic valve replacement compared with standard

treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. *Lancet* 2015;385:2485-91.

6. Mack MJ, Leon MB, Smith CR et al. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. *Lancet* 2015;385:2477-84.
7. Otto CM, Kumbhani DJ, Alexander KP et al. 2017 ACC Expert Consensus Decision Pathway for Transcatheter Aortic Valve Replacement in the Management of Adults With Aortic Stenosis: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. *J Am Coll Cardiol* 2017;69:1313-1346.
8. Yakubov SJ, Adams DH, Watson DR et al. 2-Year Outcomes After Iliofemoral Self-Expanding Transcatheter Aortic Valve Replacement in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery. *J Am Coll Cardiol* 2015;66:1327-34.
9. Nishimura RA, Otto CM, Bonow RO et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol* 2017;70:252-289.
10. Leon MB, Smith CR, Mack MJ et al. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. *N Engl J Med* 2016;374:1609-20.
11. Reardon MJ, Van Mieghem NM, Popma JJ et al. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. *N Engl J Med* 2017;376:1321-1331.
12. Thourani VH, Kodali S, Makkar RR et al. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. *Lancet* 2016;387:2218-25.
13. Mack MJ, Leon MB, Thourani VH et al. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in

# RIGHT CHOICE.



Melody™  
Transcatheter Pulmonary  
Valve (TPV) System



Not intended to constitute medical advice or in any way replace the independent medical judgment of a trained and licensed physician with respect to any patient needs or circumstances. Melody TPV is not suitable for all patients and ease of use, outcomes, and performance may vary. See the Instructions for Use for indications, contraindications, precautions, warnings, and adverse events.

Restoring lives for  
**12**  
years and counting.

The only transcatheter pulmonary valve specifically designed for RVOT conduits and bioprosthetic valves. The longest studied, with the largest body of clinical evidence at over 8 years post-implant.\* Over 12 years of implants, more than 14,000 patients' lives have been changed.

**Melody TPV — The Right Choice  
for Your Patients**

\*Melody Transcatheter Pulmonary Valve Study: Post Approval Study of the Original IDE Cohort.  
©2019 Medtronic. All rights reserved.  
UC201809495a EN 07/2019

**Medtronic**  
Further, Together

## Melody™ Transcatheter Pulmonary Valve | Ensemble™ II Transcatheter Valve Delivery System

### Important Labeling Information for the United States

**Indications:** The Melody TPV is indicated for use in the management of pediatric and adult patients who have a clinical indication for intervention on a dysfunctional right ventricular outflow tract (RVOT) conduit or surgical bioprosthetic pulmonary valve that has  $\geq$  moderate regurgitation, and/or a mean RVOT gradient  $\geq$  35 mm Hg.

**Contraindications:** None known.

### Warnings/Precautions/Side Effects

- **DO NOT implant in the aortic or mitral position. Pre-clinical bench testing of the Melody valve suggests that valve function and durability will be extremely limited when used in these locations.**
- DO NOT use if patient's anatomy precludes introduction of the valve, if the venous anatomy cannot accommodate a 22 Fr size introducer, or if there is significant obstruction of the central veins.
- DO NOT use if there are clinical or biological signs of infection including active endocarditis. Standard medical and surgical care should be strongly considered in these circumstances.
- Assessment of the coronary artery anatomy for the risk of coronary artery compression should be performed in all patients prior to deployment of the TPV.
- To minimize the risk of conduit rupture, do not use a balloon with a diameter greater than 110% of the nominal diameter (original implant size) of the conduit for pre-dilation of the intended site of deployment, or for deployment of the TPV.
- The potential for stent fracture should be considered in all patients who undergo TPV placement. Radiographic assessment of the stent with chest radiography or fluoroscopy should be included in the routine postoperative evaluation of patients who receive a TPV.
- If a stent fracture is detected, continued monitoring of the stent should be performed in conjunction with clinically appropriate hemodynamic assessment. In patients with stent fracture and significant associated RVOT obstruction or regurgitation, reintervention should be considered in accordance with usual clinical practice.

Potential procedural complications that may result from implantation of the Melody device include the following: rupture of the RVOT conduit, compression of a coronary artery, perforation of a major blood vessel, embolization or migration of the device, perforation of a heart chamber, arrhythmias, allergic reaction to contrast media, cerebrovascular events (TIA, CVA), infection/sepsis, fever, hematoma, radiation-induced erythema, blistering, or peeling of skin, pain, swelling, or bruising at the catheterization site. Potential device-related adverse events that may occur following device implantation include the following: stent fracture,\* stent fracture resulting in recurrent obstruction, endocarditis, embolization or migration of the device, valvular dysfunction (stenosis or regurgitation), paravalvular leak, valvular thrombosis, pulmonary thromboembolism, hemolysis.

\*The term "stent fracture" refers to the fracturing of the Melody TPV. However, in subjects with multiple stents in the RVOT it is difficult to definitively attribute stent fractures to the Melody frame versus another stent.

For additional information, please refer to the Instructions for Use provided with the product or available on <http://manuals.medtronic.com>.

**CAUTION:** Federal law (USA) restricts this device to sale by or on the order of a physician.

### Important Labeling Information for Geographies Outside of the United States

**Indications:** The Melody™ TPV is indicated for use in patients with the following clinical conditions:

- Patients with regurgitant prosthetic right ventricular outflow tract (RVOT) conduits or bioprostheses with a clinical indication for invasive or surgical intervention, OR
- Patients with stenotic prosthetic RVOT conduits or bioprostheses where the risk of worsening regurgitation is a relative contraindication to balloon dilatation or stenting

### Contraindications

- Venous anatomy unable to accommodate a 22 Fr size introducer sheath
- Implantation of the TPV in the left heart
- RVOT unfavorable for good stent anchorage
- Severe RVOT obstruction, which cannot be dilated by balloon
- Obstruction of the central veins
- Clinical or biological signs of infection
- Active endocarditis
- Known allergy to aspirin or heparin
- Pregnancy

**Potential Complications/Adverse Events:** Potential procedural complications that may result from implantation of the Melody device include the following: rupture of the RVOT conduit, compression of a coronary artery, perforation of a major blood vessel, embolization or migration of the device, perforation of a heart chamber, arrhythmias, allergic reaction to contrast media, cerebrovascular events (TIA, CVA), infection/sepsis, fever, hematoma, radiation-induced erythema, pain, swelling or bruising at the catheterization site. Potential device-related adverse events that may occur following device implantation include the following: stent fracture,\* stent fracture resulting in recurrent obstruction, endocarditis, embolization or migration of the device, valvular dysfunction (stenosis or regurgitation), paravalvular leak, valvular thrombosis, pulmonary thromboembolism, hemolysis.

\*The term "stent fracture" refers to the fracturing of the Melody TPV. However, in subjects with multiple stents in the RVOT it is difficult to definitively attribute stent fractures to the Melody frame versus another stent.

For additional information, please refer to the Instructions for Use provided with the product or available on <http://manuals.medtronic.com>.

The Melody Transcatheter Pulmonary Valve and Ensemble II Transcatheter Delivery System has received CE Mark approval and is available for distribution in Europe.

## medtronic.com

710 Medtronic Parkway  
Minneapolis, MN 55432-5604  
USA  
Tel: (763) 514-4000  
Fax: (763) 514-4879  
Toll-free: (800) 328-2518

**LifeLine**  
**CardioVascular Technical Support**  
Tel: (877) 526-7890  
Tel: (763) 526-7890  
Fax: (763) 526-7888  
[rs.cstechsupport@medtronic.com](mailto:rs.cstechsupport@medtronic.com)

©2019 Medtronic. All rights reserved. Medtronic, Medtronic logo, and Further, Together are trademarks of Medtronic. All other brands are trademarks of a Medtronic company.  
UC201809495a EN 07/2019

**Medtronic**



## General Pediatric Cardiologist

The Heart Center at Nationwide Children's Hospital in conjunction with The Ohio State University Department of Pediatrics in Columbus, Ohio seeks an academic general pediatric cardiologist to join our team. Clinical responsibilities include general outpatient cardiology, participation on our in-patient cardiology consultation service, and general cardiology night call. Other clinical interests may be explored.

The Heart Center is a dedicated hospital service-line that carries the mission of providing state-of-the-art, cost-effective care to our patients with congenital and acquired heart disease regardless of age. The Heart Center has >18,000 out-patient encounters per year including multiple specialty clinics (e.g. Fontan, muscular dystrophy, preventive care, cardiogenetic). The in-patient medical discharges are 1300/yr including ~400 annual surgeries. The Heart Center has 37 cardiologists and four cardiothoracic surgeons, a dedicated 20-bed CTICU and 24-bed cardiac stepdown unit, and a dedicated administration team. Excellent services in cardiac intensive and stepdown care, catheterization and intervention, non-invasive imaging, electrophysiology, heart failure and heart/heart-lung/lung transplantation are on-site. The Heart Center has a robust adult congenital heart service. The LAUNCH program is a clinical service focused on the care of patients with single ventricle. The population served includes the regional population, a large number of referred cases for advanced intervention and surgery, an extensive state-wide outpatient network (pediatric and adult congenital) and patients managed with regional partners including the newly formed Congenital Heart Collaborative. Our program is integrated with the Center for Cardiovascular Research. Nationwide Children's Hospital is a 464 bed stand-alone children's hospital and is the pediatric teaching facility for The Ohio State University School of Medicine. Columbus is the state capital and the 14th most populous city in the US (metropolitan population just over 2 million). It is a diverse community with excellent schools, a thriving economy, and a vibrant arts/food scene.

Candidates are encouraged to submit their curriculum vitae by email to:

**Robert Gajarski, MD**

Cardiology Section Chief

[RobertGajarski@nationwidechildrens.org](mailto:RobertGajarski@nationwidechildrens.org)

**Catherine Krawczeski, MD**

Cardiology Division Chief

[Catherine.Krawczeski@nationwidechildrens.org](mailto:Catherine.Krawczeski@nationwidechildrens.org)

*The Ohio State University is an Equal Opportunity, Affirmative Action Employer. Women, minorities, veterans, and individuals with disabilities are encouraged to apply.*

- Low-Risk Patients. *N Engl J Med* 2019;380:1695-1705.
14. Popma JJ, Deeb GM, Yakubov SJ et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. *N Engl J Med* 2019;380:1706-1715.
  15. Thyregod HG, Steinbruchel DA, Ihlemann N et al. Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Valve Stenosis: 1-Year Results From the All-Comers NOTION Randomized Clinical Trial. *J Am Coll Cardiol* 2015;65:2184-94.
  16. Waksman R, Rogers T, Torguson R et al. Transcatheter Aortic Valve Replacement in Low-Risk Patients With Symptomatic Severe Aortic Stenosis. *J Am Coll Cardiol* 2018;72:2095-2105.
  17. Fadahunsi OO, Olowoyeye A, Ukaigwe A et al. Incidence, Predictors, and Outcomes of Permanent Pacemaker Implantation Following Transcatheter Aortic Valve Replacement: Analysis From the U.S. Society of Thoracic Surgeons/American College of Cardiology TVT Registry. *JACC Cardiovasc Interv* 2016;9:2189-2199.
  18. Genereux P, Webb JG, Svensson LG et al. Vascular complications after transcatheter aortic valve replacement: insights from the PARTNER (Placement of AoRTic TraNscathetER Valve) trial. *J Am Coll Cardiol* 2012;60:1043-52.
  19. Kapadia SR, Huded CP, Kodali SK et al. Stroke After Surgical Versus Transfemoral Transcatheter Aortic Valve Replacement in the PARTNER Trial. *J Am Coll Cardiol* 2018;72:2415-2426.
  20. Kodali S, Pibarot P, Douglas PS et al. Paravalvular regurgitation after transcatheter aortic valve replacement with the Edwards sapien valve in the PARTNER trial: characterizing patients and impact on outcomes. *Eur Heart J* 2015;36:449-56.
  21. Leon MB, Smith CR, Mack M et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. *N Engl J Med* 2010;363:1597-607.
  22. Nazif TM, Dizon JM, Hahn RT et al. Predictors and clinical outcomes of permanent pacemaker implantation after transcatheter aortic valve replacement: the PARTNER (Placement of AoRTic TraNscathetER Valves) trial and registry. *JACC Cardiovasc Interv* 2015;8:60-9.
  23. Smith CR, Leon MB, Mack MJ et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. *N Engl J Med* 2011;364:2187-98.
  24. Webb JG, Doshi D, Mack MJ et al. A Randomized Evaluation of the SAPIEN XT Transcatheter Heart Valve System in Patients With Aortic Stenosis Who Are Not Candidates for Surgery. *JACC Cardiovasc Interv* 2015;8:1797-806.
  25. Virtanen MPO, Eskola M, Jalava MP et al. Comparison of Outcomes After Transcatheter Aortic Valve Replacement vs Surgical Aortic Valve Replacement Among Patients With Aortic Stenosis at Low Operative Risk. *JAMA Netw Open* 2019;2:e195742.
  26. Capodanno D, Petronio AS, Prendergast B et al. Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). *Eur J Cardiothorac Surg* 2017;52:408-417.
  27. Dvir D, Bourguignon T, Otto CM et al. Standardized Definition of Structural Valve Degeneration for Surgical and Transcatheter Bioprosthetic Aortic Valves. *Circulation* 2018;137:388-399.
  28. Foroutan F, Guyatt GH, Otto CM et al. Structural valve deterioration after transcatheter aortic valve implantation. *Heart* 2017;103:1899-1905.
  29. Head SJ, Mokhles MM, Osnabrugge RL et al. The impact of prosthesis-patient mismatch on long-term survival after aortic valve replacement: a systematic review and meta-analysis of 34 observational studies comprising 27 186 patients with 133 141 patient-years. *Eur Heart J* 2012;33:1518-29.
  30. Herrmann HC, Daneshvar SA, Fonarow GC et al. Prosthesis-Patient Mismatch in Patients Undergoing Transcatheter Aortic Valve Replacement: From the STS/ACC TVT Registry. *J Am Coll Cardiol* 2018;72:2701-2711.
  31. Overtchouk P, Prendergast B, Modine T. Why should we extend transcatheter aortic valve implantation to low-risk patients? A comprehensive review. *Arch Cardiovasc Dis* 2019;112:354-362.
  32. Makkar RR, Yoon SH, Leon MB et al. Association Between Transcatheter Aortic Valve Replacement for Bicuspid vs Tricuspid Aortic Stenosis and Mortality or Stroke. *JAMA* 2019;321:2193-2202.
  33. Waksman R, Corso PJ, Torguson R et al. TAVR in Low-Risk Patients: 1-Year Results From the LRT Trial. *JACC Cardiovasc Interv* 2019;12:901-907.
  34. George I, Kodali SK, Leon MB. Changing the Conversation to TAVR First!: Aftermath of the Low-Surgical Risk TAVR Studies. *JACC Cardiovasc Interv* 2019;12:908-910.
  35. Chakravarty T, Sondergaard L, Friedman J et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. *Lancet* 2017;389:2383-2392.
  36. Sondergaard L, Ihlemann N, Capodanno D et al. Durability of Transcatheter and Surgical Bioprosthetic Aortic Valves in Patients at Lower Surgical Risk. *J Am Coll Cardiol* 2019;73:546-553.
  37. Gleason TG, Reardon MJ, Popma JJ et al. 5-Year Outcomes of Self-Expanding Transcatheter Versus Surgical Aortic Valve Replacement in High-Risk Patients. *J Am Coll Cardiol* 2018;72:2687-2696.
  38. Prendergast BD, Redwood SR. Transcatheter Aortic Valve Replacement. *Circulation* 2019;139:2724-2727.
  39. Tang GHL, George I, Bapat VN. Structural Valve Deterioration in Surgical Versus Transcatheter Aortic Valve Replacement: Comparing Apples to Oranges? *J Am Coll Cardiol* 2019;73:2785.
  40. Ndunda PM, Vindhya MR, Muutu TM, Fanari Z. Clinical outcomes of sentinel cerebral protection system use during transcatheter aortic valve replacement: A systematic review and meta-analysis. *Cardiovasc Revasc Med* 2019.

41. Selnes OA, Gottesman RF, Grega MA, Baumgartner WA, Zeger SL, McKhann GM. Cognitive and neurologic outcomes after coronary-artery bypass surgery. *N Engl J Med* 2012;366:250-7.
42. Tang GH, Lansman SL, Panza JA. Beyond PARTNER: appraising the evolving trends and outcomes in transcatheter aortic valve replacement. *Cardiol Rev* 2015;23:1-10.
43. Thyregod HGH, Ihlemann N, Jorgensen TH et al. Five-Year Clinical and Echocardiographic Outcomes from the Nordic Aortic Valve Intervention (NOTION) Randomized Clinical Trial in Lower Surgical Risk Patients. *Circulation* 2019.
44. Massoullie G, Bordachar P, Ellenbogen KA et al. New-Onset Left Bundle Branch Block Induced by Transcatheter Aortic Valve Implantation. *Am J Cardiol* 2016;117:867-73.
45. Nazif TM CS, George I, et al. New-onset left bundle branch block after transcatheter aortic valve replacement is associated with adverse long-term clinical outcomes in intermediate-risk patients: an analysis from the PARTNER II trial. *Eur Heart J* 2019;0:1-12.
46. Urena M, Rodes-Cabau J. New-onset conduction disturbances: the last obstacle in the way of transcatheter aortic valve implantation. *Eur Heart J* 2019.
47. Tang GHL, Zaid S, Ahmad H, Undemir C, Lansman SL. Transcatheter Valve Neo-Commissural Overlap With Coronary Orifices After Transcatheter Aortic Valve Replacement. *Circ Cardiovasc Interv* 2018;11:e007263.
48. Yudi MB, Sharma SK, Tang GHL, Kini A. Coronary Angiography and Percutaneous Coronary Intervention After Transcatheter Aortic Valve Replacement. *J Am Coll Cardiol* 2018;71:1360-1378.
49. Tang GHL, Zaid S, Gupta E, et al. Feasibility of Repeat Transcatheter Aortic Valve Replacement (TAVR) after Sapien 3 TAVR (TAV-in-TAV): A Novel Classification Scheme and Pilot Angiographic Study. *JACC Cardiovasc Interv* 2019.
50. Tang GHL, Zaid S, Gupta E, et al. Impact of Initial Evolut Transcatheter Aortic Valve Replacement Deployment Orientation on Final Valve Orientation and Coronary Reaccess: A Pilot Study. *Circ Cardiovasc Interv* 2019;12:e008044.
51. Testa L, Fiorina C, Giannini C, et al. Valve Performance and echocardiographic data throughout 8 years follow up after TAVR. *EuroPCR*. Paris, France, 2019.
52. Sathananthan J, Lauck S, Polderman J, et al. Ten year follow-up of patients treated with transcatheter aortic valve implantation. *EuroPCR*. Paris, France, 2019.
53. Midha PA, Raghav V, Sharma R et al. The Fluid Mechanics of Transcatheter Heart Valve Leaflet Thrombosis in the Neosinus. *Circulation* 2017;136:1598-1609.
54. Allen KB, Chhatriwalla AK, Cohen DJ et al. Bioprosthetic Valve Fracture to Facilitate Transcatheter Valve-in-Valve Implantation. *Ann Thorac Surg* 2017;104:1501-1508.
55. Khan JM, Greenbaum AB, Babaliaros VC et al. The BASILICA Trial: Prospective Multicenter Investigation of Intentional Leaflet Laceration to Prevent TAVR Coronary Obstruction. *JACC Cardiovasc Interv* 2019;12:1240-1252.
56. Regueiro A, Linke A, Latib A et al. Association Between Transcatheter Aortic Valve Replacement and Subsequent Infective Endocarditis and In-Hospital Death. *JAMA* 2016;316:1083-92.
57. Moriyama N, Laakso T, Biancari F et al. Prosthetic valve

- endocarditis after transcatheter or surgical aortic valve replacement with a bioprosthesis: results from the FinnValve Registry. *EuroIntervention* 2019.
58. Kolte D, Goldsweig A, Kennedy KF et al. Comparison of Incidence, Predictors, and Outcomes of Early Infective Endocarditis after Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement in the United States. *Am J Cardiol* 2018;122:2112-2119.
59. Yeo I, Kim LK, Park SO, Wong SC. In-hospital infective endocarditis following transcatheter aortic valve replacement: a cross-sectional study of the National Inpatient Sample database in the USA. *J Hosp Infect* 2018;100:444-450.






**Gilbert H. L. Tang, MD, MSc, MBA**  
*Corresponding Author  
 Surgical Director, Structural Heart  
 Program Mount Sinai Health System  
 Department of Cardiovascular Surgery  
 1190 Fifth Avenue, GP2W, Box 1028  
 New York, NY, USA  
 T. 212.659.6800 F. 212.659.6818  
 gilbert.tang@mountsinai.org*



**Aditya Sengupta, MD**  
*Cardiothoracic Surgery Resident  
 Icahn School of Medicine at Mount Sinai  
 Mount Sinai Health System  
 New York, NY, USA*



**Sophia L. Alexis, MD**  
*Cardiothoracic Surgery Resident  
 Icahn School of Medicine at Mount Sinai  
 Mount Sinai Health System  
 New York, NY, USA*



## Called to Care

### Pediatric Cardiology/Interventional Cardiology Opportunity Sioux Falls, SD

#### PRACTICE DETAILS

Sanford Children's Specialty Clinic, a multispecialty pediatric clinic, is seeking a BC/BE Interventional Pediatric Cardiologist to add depth to the existing program.

- Join three other Pediatric Cardiologists. Sanford Children's Specialty clinic is a well-established, full range practice. This very busy and growing practice is particularly interested in physicians who share their philosophy to establish strong relationships with patients, their families and relate well to referring physicians and colleagues.
- Ideal opportunity for an individual who desires to have an academic environment in a primarily clinical practice. Teaching medical students, pediatric residents, and adult cardiology fellows is expected.
- Training in interventional catheterizations would be preferred.
- Outpatient and inpatient services, including pediatric and adult congenital cardiology.
- Largest pediatric sub-specialty group in the region consisting of 60+ pediatric sub-specialists.

#### SANFORD HEALTH SYSTEM

Sanford Health is one of the largest, not-for-profit health care systems in the nation with 44 hospitals and nearly 300 clinics in nine states and nine countries. Sanford Health serves the Upper Midwest, with nearly 1,400 physicians in 81 specialty areas of medicine.

#### ABOUT SANFORD HEALTH IN SIOUX FALLS

- 545-bed hospital
- Large referral area
- Research opportunities
- Serving a city population of 250,000

#### SIOUX FALLS COMMUNITY

Sioux Falls is one of the fastest growing areas in the Midwest. As the largest city in the state, it balances an excellent quality of life and strong economy with a safe, clean living environment. The cost of living is competitive and South Dakota has no state income tax. Sioux Falls offers amenities of a community twice its size such as fine dining, shopping, arts, sports and nightlife.

#### TO LEARN MORE, PLEASE CONTACT:

Mary Jo Burkman, DASPR  
 Sr. Director Physician Recruitment (605)328-6996  
 mary.jo.burkman@sanfordhealth.org

[practice.sanfordhealth.org](http://practice.sanfordhealth.org)

019054-00087 10/18

**SANFORD**  
HEALTH

# A Melody for the Elderly

By Aphrodite Tzifa, MD, FRCPC; Dimosthenis Avramidis, MD; Dimitra Loggitsi, MD, PhD; Konstantinos Spargias, MD, PhD

Transcatheter implantation of pulmonary valves for treatment of Right Ventricular Outflow Tract dysfunction was first reported in 2000<sup>1</sup>. Since then, over 10,000 patients have received transcatheter therapy with a Melody percutaneous valve for failed pulmonary conduits. The vast majority of these patients have been children or young adults, mostly because Complex Congenital Heart Disease surgery started taking place after the 1970's. However, older patients who have received a pulmonary conduit for other indications, such as the Ross




Figure 1. Transparent Volume-Rendering image (VRT) - Lateral RVOT view with demonstration of the heavily calcified homograft.




Figure 2. CT angiographic image with planimetric measurement of the effective area of the calcified pulmonary homograft.

procedure for Aortic Valve Disease, may present with conduit failure at a more advanced age. A contributing factor to the latter is also the fact that the pulmonary homograft longevity is superior in the Ross setting rather than in other Congenital Heart Disease entities<sup>2</sup>.

We report the case of an 81-year-old patient who presented with pulmonary homograft dysfunction and received transcatheter valve therapy in the pulmonary position with the use of a 22mm Melody valve inside a 31-year old pulmonary homograft. To the best of our knowledge, this is the oldest patient to date who has received transcatheter pulmonary valve implantation therapy.

The patient presented with aortic stenosis at the age of 50 years and underwent a Ross operation in 1986 by Professor Donald Ross. His homograft was noted to be calcified and stenosed 14 years later, but due to good clinical condition, the patient had refused a re-operation. He remained under frequent follow-up and became symptomatic with clinical signs of pedal oedema and ascites, requiring multiple hospitalisations, one year before the patient was referred for transcatheter therapy.

Non-invasive imaging with CT and MRI showed a heavily calcified and stenosed homograft (Figures 1,2), with the coronary arteries at a safe distance from the area of interest (Figure 3a, b). Echocardiographic peak Doppler derived pressure gradient across the pulmonary homograft was 60mmHg and pulmonary regurgitant fraction as assessed by MRI phase contrast flows was 28%. Right ventricular ejection fraction was 55% and RVEDV measured 115ml/m<sup>2</sup>. Due to advanced age and multiple vascular operations, the patient also underwent an MRI assessment of his femoral veins to delineate the vascular anatomy and to choose the entry point for insertion of the 22Fr Melody Ensemble system. The procedural steps were the usual with pre-implantation of a covered stent followed by implantation of a 22mm Melody valve. Although the 31-year old homograft was heavily calcified, the stent and valve were implanted without any disruption to the calcified homograft wall. After valve implantation, haemodynamic assessment revealed an RV-PA pressure gradient drop from 40mmHg to 5mmHg, whilst MPA angiogram showed no residual pulmonary valve regurgitation.

The patient did not need admission to the ICU and was discharged home from the ward after 48 hours. He improved significantly post-procedure, and at 1-month follow-up, his ascites had therapy resolved completely, whilst diuretic decreased from a combination of three drugs to just 20mg of Furosemide once a day.

## Discussion

Transcatheter valve implantation has become routine therapy for elderly patients with Aortic Valve Disease<sup>3</sup> and for selected

congenital patients with pulmonary or Tricuspid Valve Disease<sup>4</sup>. Moreover, reports of hybrid or transcatheter implantation of valves in the mitral position have been on the rise<sup>5</sup>. The benefit of a transcatheter approach versus open-heart revaluation is greater in multi-operated patients with significant co-morbidities or in patients of advanced age. Valve-in-valve therapy in the pulmonary position has received approval when a homograft or conduit has already been implanted during previous surgery and has become dysfunctional. The life-span of a pulmonary homograft is usually between 10-20 years, as they most frequently get stenosed, regurgitant or both, due to calcification.

Our report depicts the wide age span that transcatheter valve therapy in the





Figure 3. 3D-CT angiographic assessment of the coronary arteries in relation to the pulmonary homograft, anterior (3a) and left lateral (3b) view.

pulmonary position may be suitable for. It also highlights the need for close collaboration between Adult and Congenital Cardiologists, as patients who might benefit from transcatheter pulmonary valve therapy can be found even amongst the elderly. This is particularly important as modern transcatheter therapies are continuously expanding their potential applications and, on the other hand, the congenital population is growing older.

## References

1. Lurz P, Bonhoeffer P. Percutaneous implantation of pulmonary valves for treatment of right ventricular outflow tract dysfunction. *Cardiol Young*. 2008 Jun;18(3):260-7.
2. Forbess JM, Shah AS, St Louis JD, Jagers JJ, Ungerleider RM. Cryopreserved homografts in the pulmonary position: determinants of durability. *Ann Thorac Surg*. 2001 Jan;71(1):54-9.
3. Piazza N, Bleiziffer S, Brockmann G, Hendrick R, Deutsch MA, Opitz A, Mazzitelli D, Tassani-Prell P, Schreiber C, Lange R. Transcatheter aortic valve implantation for failing surgical aortic bioprosthetic valve: from concept to clinical application and evaluation (part 1). *JACC Cardiovasc Interv* 2011 Jul;4(7):721-32.
4. McElhinney DB, Cabalka AK, Aboulhosn JA, Eicken A, Boudjemline Y, Schubert S, Himbert D, Asnes JD, Salizzoni S, Bocks ML, Cheatham JP, Momenah TS, Kim DW, Schranz D, Meadows J, Thomson JD, Goldstein BH, Crittendon I 3rd, Fagan TE, Webb JG, Horlick E, Delaney JW, Jones TK, Shahanavaz S, Moretti C, Hainstock MR, Kenny DP, Berger F, Rihal CS, Dvir D; Valve-in-Valve International Database (VIVID) Registry. Transcatheter tricuspid valve-in-valve implantation for the treatment of dysfunctional surgical bioprosthetic valves: an international, multicenter registry study. *Circulation*. 2016;133(16):1582-93.
5. Guerrero M, Dvir D, Himbert D, Urena M, Eleid M, Wang DD, Greenbaum A, Mahadevan VS,



## Pediatric Cardiologist

The Department of Pediatrics at Southern Illinois University School of Medicine is recruiting an M.D. for a fourth pediatric cardiologist at the Assistant Professor level. Faculty will join a rapidly expanding cardiology program at our Children's Hospital, an 80 bed CHA affiliated pediatric referral center for Central and Southern Illinois with a referral base of almost 2 million. The current program includes state-of-the-art noninvasive imaging in TTE, TEE, fetal echocardiogram, and advanced MRI imaging. We have developed a highly successful collaborative clinical and research program with a nationally recognized pediatric cardiology center. Opportunities exist to participate in resident and medical student education and receive an advanced degree in medical education. Candidates must be board eligible in Pediatrics and Pediatric Cardiology. Illinois licensure is required prior to official start date. Travel in central Illinois to outreach clinics is required.

Applications are accepted online at:  
<https://siumed.hiretouch.com>

For additional information, please contact:  
**Ramzi Nicolas, MD**  
T. 217.545.9706  
[rnicolos@siumed.edu](mailto:rnicolos@siumed.edu)

SIU is an EO/AA employer

Holzhey D, O'Hair D, Dumonteil N, Rodés-Cabau J, Piazza N, Palma JH, DeLago A, Ferrari E, Witkowski A, Wendler O, Kornowski R, Martinez-Clark P, Ciaburri D, Shemin R, Alnasser S, McAllister D, Bena M, Kerendi F, Pavlides G, Sobrinho JJ, Attizzani GF, George I, Nickenig G, Fassa AA, Cribier A, Bapat V, Feldman T, Rihal C, Vahanian A, Webb J, O'Neill W.

6. Transcatheter mitral valve replacement in native mitral valve disease with severe mitral annular calcification: Results from the first multicenter global registry. *JACC Cardiovasc Interv.* 2016;9(13):1361-71.



**Aphrodite Tzifa, MD, FRCPCH**

*Director of Department of Congenital Heart Disease  
Mitera Hospital, Hygeia Hospital Groups  
Athens, Greece  
T. +302106869788  
A.Tzifa@btinternet.com*



**Dimosthenis Avramidis, MD**

*Department of Congenital Heart Disease  
Mitera Hospital, Hygeia Hospital Groups  
Athens, Greece*



**Dimitra Loggitsi, MD, PhD**

*Department of Radiology  
Mitera Hospital, Hygeia Hospital Groups  
Athens, Greece*



**Konstantinos Spargias, MD, PhD**

*Division of Transcatheter Valve Therapies  
Hygeia Hospital  
Athens, Greece*



**CONGENITAL  
CARDIOLOGY  
TODAY**

**HOSPITAL  
DIRECTORY  
2019**

**Congenital Cardiac Care  
Providers in North America  
Offering Open Heart  
Surgery for Children**



**The 2019 Hospital Directory  
is now available on CCT's  
website. Check it out today!**

**[www.congenitalcardiologytoday.com/  
2019/09/03/hospital-directory-2019](http://www.congenitalcardiologytoday.com/2019/09/03/hospital-directory-2019)**



**Seattle Children's**  
HOSPITAL · RESEARCH · FOUNDATION

**Clinical Associate Professor or Clinical Professor**

The University of Washington, Department of Pediatrics, Division of Cardiology is accepting applications for a full time Clinical Associate Professor or Clinical Professor.

Responsibilities include directing our Acute Care Cardiology Program at Seattle Children's Hospital. The Acute Care Cardiology Program includes medical and surgical cardiac patients admitted to our acute care cardiology service, as well as consultative services to the cardiac, neonatal, and pediatric intensive care units. The role will also involve individual general cardiology night and weekend call and outpatient clinic.

The successful candidate will have earned an MD/DO (or foreign equivalent) and be board certified/board eligible in Pediatric Cardiology.

In order to be eligible for University sponsorship for an H-1B visa, graduates of foreign (non-U.S.) medical schools must show successful completion of all three steps of the U.S. Medical Licensing Exam (USMLE), or equivalent as determined by the Secretary of Health and Human Services.

The successful candidate will be an experienced cardiologist with strong clinical skills who also has the leadership skills and the vision to direct our acute care cardiology program at Seattle Children's Hospital.

University of Washington faculty engage in teaching, research, and service.

Please apply at <https://apply.interfolio.com/62460>

**Associate Professor (WOT) or Full Professor (WOT)**

The University of Washington, Department of Pediatrics, Division of Cardiology is accepting applications for a full time Associate Professor (WOT) or Full Professor (WOT).

Responsibilities include directing our Acute Care Cardiology Program at Seattle Children's Hospital. The Acute Care Cardiology Program includes medical and surgical cardiac patients admitted to our acute care cardiology service, as well as consultative services to the cardiac, neonatal, and pediatric intensive care units. The role will also involve individual general cardiology night and weekend call and outpatient clinic.

The successful candidate will have earned an MD/DO (or foreign equivalent) and be board certified/board eligible in Pediatric Cardiology.


In order to be eligible for University sponsorship for an H-1B visa, graduates of foreign (non-U.S.) medical schools must show successful completion of all three steps of the U.S. Medical Licensing Exam (USMLE), or equivalent as determined by the Secretary of Health and Human Services.

The successful candidate will be an experienced cardiologist with strong clinical skills who also has the leadership skills and the vision to direct our acute care cardiology program at Seattle Children's Hospital.

University of Washington faculty engage in teaching, research, and service.

Please apply at <https://apply.interfolio.com/62452>

*EO employer – M/F/Vets/Disabled*



# NuDEL™

Triaxial BIB Catheter  
with Sheath & Covered  
CP Stent for the Aorta\*

## The All-In-One Aortic Stent System

**The NuDEL™ Stent Delivery System is designed for the efficient and effective treatment of Coarctation of the Aorta.**

The NuDEL includes a triaxial balloon in balloon designed catheter with a Covered Mounted CP Stent™, which is then covered by a sheath as an all-in-one system. Combining the proven technologies of our NuMED BIB® balloon catheter and our Covered CP Stent™, the NuDEL System employs both our compact delivery method and the “zig” pattern stent design.

The NuDEL System is available for immediate purchase in the EU. Contact us or your local distributor to place an order.

# NuMED

World Leader in Pediatric Cardiology

NuMED, Inc. | 2880 Main Street | Hopkinton, NY 12965 USA

Tel: 315.328.4491 | Fax: 315.328.4941 | [www.numedforchildren.com](http://www.numedforchildren.com)



# Medical News, Products & Information

*Compiled and Reviewed by Kate Baldwin and Tony Carlson*

## **B. Braun Interventional Systems Expands its Congenital and Structural Heart Portfolio With the EmeryGlide MR Conditional Guidewire From Nano4Imaging**

B. Braun Interventional Systems Inc. (BIS), a company dedicated to providing innovative solutions in the field of congenital and structural interventional cardiology, today announced it has signed an exclusive US distribution agreement with Nano4imaging for their EmeryGlide™ guidewire.

The EmeryGlide MR conditional guidewire is the latest cutting-edge addition to BIS' congenital and structural heart portfolio. “We are excited to collaborate with Nano4imaging to bring to the U.S. market this compelling product and procedural innovation to perform MRI guided interventions,” said Dave Mittl, B. Braun Interventional Systems Corporate Director of New Business Development. “Our team continues to invest its resources into being at the forefront of providing clinicians with clinically relevant innovations in the area of congenital and structural heart care.”

The EmeryGlide is an MR conditional guidewire that enables MRI guided cardiac catheterizations. Under defined conditions, the wire can be used in combination with MR compatible products for the introduction or placement of diagnostic catheters or other interventional devices. The EmeryGlide is the only MR conditional guidewire available in the United States.

“We are glad that with B. Braun Interventional Systems as a strong new partner, our EmeryGlide will find its way to the U.S. pediatric market with the ability to extend to other interventional MRI applications,” commented Christoph

Manegold, CEO, Nano4imaging USA, LLC.

Real-time magnetic resonance imaging (MRI) guidance enables excellent soft tissue visualization and does not use ionizing radiation to perform diagnostic and interventional cardiac catheterizations, a particularly important consideration in congenital heart defect patients who often need multiple procedures throughout their lifetime, including X-ray-dependent cardiac catheterization. In addition to reduced X-ray exposure for patients and clinicians, MRI enables additional and more detailed imaging, which in many cases improves diagnostics.

“Cardiac catheterization in the MRI suite has been primarily limited to diagnostic procedures due to lack of MRI compatible guidewires and other interventional equipment. The availability of the EmeryGlide guidewire in the United States, the only 510(k) cleared MR conditional guidewire, has enabled me and some of my other iCMR colleagues to advance catheters to places that were previously not possible, especially in complex congenital heart disease patients,” said Dr. Suren Reddy from UT Southwestern/Children’s Medical Center, Dallas. “This guidewire has the potential to significantly advance the field of MR guided cardiac catheterizations and interventions.”

## **Dr. Madhav Swaminathan Elected President of the American Society of Echocardiography**

Madhav Swaminathan, MD, MBBS, MMCI, FASE, has taken the helm as President of the American Society of Echocardiography (ASE). His presidency, which will last one year, marks the first time that an anesthesiologist has been elected to head ASE in its 44-year history.

Dr. Swaminathan addressed the members of the Society at their annual business meeting and shared his excitement for leading ASE for the next year. He said, “ASE has taken an unprecedented step of tapping the first anesthesiologist as its president. It is a bold statement about celebrating diversity. I look forward to leading the Society that has opened its arms to everyone who is interested in cardiovascular ultrasound. In addition to guiding ASE into a new strategic plan beginning in 2020, I am committed to building a network of leaders that supports the well-being of the entire cardiovascular ultrasound community.”

Dr. Swaminathan is Board-Certified in Anesthesiology and Perioperative Transesophageal Echocardiography. He is Vice Chair for Faculty Development, Duke Anesthesiology, and Professor of Anesthesiology, Duke University School of Medicine. He joined the faculty at Duke in 2002 and rose rapidly to the rank of professor with tenure, winning teaching and community service awards along the way. Administratively, he served as Director, Perioperative Echocardiography Service from 2004-2014, where he transformed Duke’s research in echocardiography, developed new echo educational initiatives, and brought practitioners of cardiovascular ultrasound together. In his role as the vice chair for faculty development, he is responsible for nurturing the faculty with the vision, mentorship, opportunities, and infrastructure they need to be leaders in changing the face of perioperative medicine. His research interests focus on diastolic dysfunction as well as kidney outcomes after cardiac surgery. He has published over 160 papers in peer-reviewed journals and has written several editorials and book chapters, and is a co-editor of a popular textbook on perioperative echocardiography.

In 2015, Dr. Swaminathan was named the 16th Feigenbaum Lecturer at the ASE Scientific Sessions. This was the first time an anesthesiologist was given this honor, which is awarded to a



Madhav Swaminathan, MD, MBBS, MMCi, FASE, has taken the helm as President of the American Society of Echocardiography (ASE).

young investigator in recognition of their significant contributions to research in the field of cardiovascular ultrasound and their potential to continue at a high level of achievement. Dr. Swaminathan has held many significant roles on ASE committees, including chair of the Membership Committee and chair of the Council on Perioperative Echocardiography (COPE). He has also served on the Industry Relations Committee, Education Committee, and as co-chair and chair of the Perioperative Echocardiography track for ASE's Scientific Sessions from 2011-2015. He currently serves on the editorial board of CASE, ASE's cardiovascular imaging case reports journal. He has participated on other writing groups and taskforces, including Governance, Public Relations, and Non-Traditional Users.

Dr. Swaminathan is active in a number of other professional societies, including the American Medical Association, the Society of Cardiovascular Anesthesiologists, the American Heart Association, the Association of University Anesthesiologists, and the International Anesthesia Research Society.

He attended college in India, earning an MBBS with distinction at Delhi University. He completed residencies and fellowships in anesthesia and

cardiac anesthesia at Catholic University of Louvain, Belgium, the Royal Victoria Hospitals Trust, Belfast, UK, and Duke University, Durham, NC. He has also received a Master of Management in Clinical Informatics from Duke University in 2016.

Dr. Swaminathan served as ASE's vice President and President-Elect prior to ascending to President. Joining him as new members of the 2019-2020 Executive Committee are Vice President, Raymond Stainback, MD, FASE, Texas Heart Institute, Baylor St. Luke's Medical Center, Houston, TX; and Secretary, Matt Umland, ACS, RDCS, FASE, Aurora Healthcare, Aurora, WI.

Continuing ASE officers include: President-Elect, Judy Hung, MD, FASE, from Massachusetts General Hospital, Boston, MA; Council Representative, Wyman Lai, MD, MPH, FASE, CHOC Children's Hospital, Orange, CA; and Treasurer, Carol Mitchell, PhD, RDMS, RDCS, RVT, RT(R), ACS, FASE, University of Wisconsin Hospital, Madison, WI, and Immediate Past President, Jonathan R. Lindner, MD, FASE, of Oregon Health & Science University, Portland, OR.

In addition to the new officers, the ASE membership has elected the following new board of directors members to two-year terms: Piers Barker, MD, FASE, Duke University Medical Center, Durham, NC (Pediatric Council Steering Committee Chair); Alina Nicoara, MD, FASE, Duke University Medical Center, Durham, NC (Perioperative Council Steering Committee Chair); Alan S. Pearlman, MD, FASE, Seattle, WA (Past President); Peter Rahko, MD, FASE, University of Wisconsin, Milwaukee, WI; Jennifer Schaaf, BS, ACS, RDCS, FASE, The Christ Hospital Health Network, Cincinnati, OH; Vandana Sachdev, MD, FASE, National Institute of Health, Bethesda, MD; and Cathy West, MSc, DMU (CARDIAC), AMS, EACVI CHD, FASE, Royal Brompton Hospital, London, UK (International). Geoffrey Rose, MD, FASE, Sanger Heart & Vascular Center, Charlotte, NC, will also serve on the board after being reappointed for his exceptional service.



### Pediatric Non-Invasive Cardiologist

Capital District Pediatric Cardiology Associates is recruiting for a BC/BE Pediatric Non-Invasive Cardiologist for July, 2020. As the pediatric cardiology section at Albany Medical College, we have a diverse medical and pediatric cardiac surgical program. Our surgical outcomes as reported by both New York state and STS databases are excellent. The ideal candidate should be able to function independently to provide transthoracic, transesophageal and fetal echocardiography. Additionally, the candidate should be comfortable with busy clinical responsibilities as a general pediatric cardiologist, including inpatient service coverage at Albany Medical Center, staffing outpatient clinics, performing and interpreting transthoracic echocardiograms and sharing on call duties. Academic responsibilities are primarily teaching, which includes medical students, residents, adult cardiology fellows, and physician assistant and RN students. Opportunities for research are available through Albany Medical College and numerous other academic and state institutions nearby. While we hold academic titles in the Department of Pediatrics at Albany Medical College, our group is organized and managed privately. Located in upstate NY, Albany is a family friendly city with abundant four season outdoor and cultural activities, with easy proximity to New York City, Boston and Montreal.

Interested candidates should direct inquiries to:

**Steven Kamenir, MD**  
skamenir@nykidshearts.com

## MaineHealth Physician Recruitment Center Congenital Cardiologist with Focus on Adult Congenital Cardiology

Congenital Heart has been the premier Congenital Cardiology Practice in the state of Maine for over 50 years. We are excited to announce that Congenital Heart has partnered with Maine Medical Partners and MaineHealth to continue providing state-of-the-art care for children and adults with congenital heart disease. This partnership will form the new Division of Pediatric Cardiology and Congenital Heart Care at Maine Medical Center. Commensurate with this partnership is the opportunity to formalize an Adult with Congenital Heart Disease (ACHD) program to serve the burgeoning population of ACHD in Maine.


The candidate would be BE/BC in Pediatric Cardiology and BE/BC in ACHD with appropriate academic appointments. Responsibilities would include developing and directing an ACHD service that would provide both inpatient consultative services and outpatient care through multidisciplinary clinics with the expectation of having the program accredited. There would be close collaboration with the Adult Cardiology Service as well as with comprehensive subspecialty services both in Pediatrics and Adult Medicine at Maine Medical Center. This program has been deemed a priority by the institution with proforma data to support additional hires for the service as needed.

A research interest is encouraged with opportunities for collaboration with established research institutes like the Maine Medical Cardiovascular Research Institute (MMCRI). Call responsibilities would be 1:5 nights and include being a congenital consultant in the post-operative PICU, caring for service patients on the ward, and fielding calls from outpatients in our practice and from ER's throughout the state.

The candidate will join 6 other Pediatric Cardiologists, who have established the only comprehensive Congenital Heart program in the state of Maine. The program has recently hired an experienced surgeon to serve as the Director of Congenital Cardiac Surgery. After providing comprehensive congenital surgical care in the state for the past 25 years, the new Director has ensured that the infrastructure is in place to continue providing excellent surgical care. Comprehensive interventional services have been provided for over 20 years with all FDA-approved devices and procedures, including transcatheter pulmonary valve insertion being performed. The program also performs state-of-the-art imaging including fetal, TTE, TEE, CMRI and CTA.

Maine Medical Center (MMC) has 637 licensed beds and is the state's leading tertiary care hospital and Level One Trauma Center, with a full complement of Residencies and Fellowships and an integral part of Tufts University Medical School.

Situated on the Maine coast, Portland offers the best of urban sophistication combined with seaside charm. The Old Port area receives tourists from around the world with nationally recognized restaurants, breweries, and hotels. In fact, Portland was recently named "2018 Restaurant City of the Year" by Bon Appétit Magazine. The area has an active outdoor community providing four-season recreational opportunities such as skiing, hiking, sailing, and miles of beautiful beaches. Just two hours north of Boston, this is an exceptionally diverse and vibrant community.



For more information, please contact Gina Mallozzi, Physician Recruiter, at 207.661.2092 or [gmallozzi@mainehealth.org](mailto:gmallozzi@mainehealth.org)

## Edwards PASCAL Transcatheter System Receives CE Mark

PRNewswire – Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for Structural Heart Disease and Critical Care monitoring, today announced the Edwards PASCAL transcatheter valve repair system has received a CE Mark for the treatment of patients with mitral regurgitation.

“Mitral valve disease is complex, varied and prevalent, and patients are in significant need of multiple safe and effective therapies to treat debilitating symptoms that can lead to a high rate of mortality,” said Bernard J. Zovighian, Edwards’ Corporate Vice President, Transcatheter Mitral and Tricuspid Therapies. “The introduction of the PASCAL system to clinicians and patients in Europe provides a differentiated, minimally-invasive therapy to address the needs of patients with mitral regurgitation.”


The PASCAL system is designed for effective reduction of mitral regurgitation while respecting the native anatomy. It features contoured, broad paddles to maximize coaptation of the mitral leaflets, and a central spacer that fills the regurgitant orifice area. The delivery system allows for independent leaflet capture and the ability to optimize leaflet position.

“The PASCAL system is uniquely designed for optimized valve leaflet capture and coaptation, and to help operators achieve their ultimate goal of safe and effective mitral regurgitation reduction for their patients,” said Konstantinos Spargias, THV Director, Hygeia Hospital, Greece, and an investigator in the multi-national prospective CLASP Study.

The PASCAL system is one of multiple transcatheter repair or replacement therapies designed to address mitral and tricuspid valve diseases that are under development by Edwards. It represents the culmination of 20 years of innovation by Edwards to develop a novel, differentiated and advanced platform for patients in need. The company is building upon a long history of knowledge, experience and commitment to advance transformative therapies and develop a robust body of clinical evidence.

The PASCAL system is not approved in the United States; the CLASP IID U.S. pivotal trial is currently enrolling patients with symptomatic primary mitral regurgitation.

Dr. Spargias is a consultant to Edwards Lifesciences.



## Congenital Reporting & Imaging Solutions for Cath, Echo and MR

Extensive library of modifiable Mullins diagrams with 300+ exclusive to Digisonics

Trend plots with pediatric and fetal z-scores

Quick report capability for bringing forward data from previous reports

Robust data mining and business analytics package

[www.digisonics.com](http://www.digisonics.com)

## Geneva Health Solutions Hits Critical Milestones Driving Growth; Predicts Cardiac Data Explosion in 2019

Geneva Health Solutions (GHS), the leading cloud-based technology platform and service for managing data from implantable cardiac devices, announces triple-digit revenue growth in 2018, an indicator of the explosive growth of implantable cardiac device data expected in 2019. This year, GHS has also tripled its client base and workforce, quadrupled the number of devices being monitored through its service and increased its revenue more than ten-fold.

“Data deluge from implanted cardiac devices has hit critical mass for cardiac practices, physicians and staff, and our ability to become an extension of their team and implement an effective remote monitoring program is truly improving patient care,” said Yuri Sudhakar, CEO of Geneva Health Solutions. “Armed with actionable information every day, cardiologists can pro-actively reach out to patients with device issues and arrhythmias like atrial fibrillation and heart failure diagnostics well in advance of a significant health problem.”

The GHS patent-pending platform aggregates cardiac device data from all major implantable cardiac device manufacturers’ remote monitoring portals and in-office checks. The GHS remote monitoring service helps providers manage the incoming data and alerts, improves patient compliance and has significant clinical benefits including the early detection of device issues and arrhythmias as well as a reduction in hospitalizations, and thus patient care costs.

Significant Milestones for 2018 Include:

- Forty-four New Cardiology Sites in 2018 – Geneva Health Solutions’ client list has grown from 16 clinics to over 65 cardiology sites in one year, with 45 of those sites also using the Geneva Health Solutions Remote Monitoring Service.
- Improved Remote Monitoring Pathway Financials – GHS eliminates workflow inefficiencies, optimizes reimbursement, and provides device clinic resource support to ensure clinics can properly implement the remote monitoring standard of care. With the GHS service, cardiology providers have experienced over a 70% improvement in the profitability for the standard of care by optimizing reimbursement and reducing costs.
- Increased Patient Outreach – Today, more than 30,000 are being monitored by the GHS Remote Monitoring Service, a 4x growth from last year. GHS has become an extension of the device clinic, assisting overextended clinic staff, improving patient adherence and compliance as well as mitigating liability.
- Geneva University Founded in 2018 – Geneva University is a rigorous training program in data analytics and preparation for cardiac device technicians to help them achieve the highest standards in cardiac remote monitoring.
- Employee Growth – In response to the company’s unprecedented growth, GHS nearly tripled its employee



## Heart Failure/Transplant Cardiologist

The Heart Center (THC) at Nationwide Children’s Hospital is recruiting a cardiologist, at the assistant or associate professor level, to participate as part of the advanced heart failure and transplant team. This individual would join a group of three academic cardiologists, two nurse practitioners, two transplant nurse coordinators, and allied healthcare providers who serve our cardiomyopathy/heart failure/transplant population.

Candidates must be board-eligible or certified in pediatric cardiology. Candidates who have completed advanced training in heart failure and transplantation with an established academic portfolio or strong academic potential are preferred. The successful candidate will participate with our team in the care of patients with advanced heart failure including those requiring mechanical assist with VADs and transplant while working closely with members of our cardiac intensive care unit, out-patient services, and our referral partners in an effort to ensure high-quality and effective care delivery for these high-risk patients. In the last year, the program evaluated over 1,200 outpatients across Heart Failure, Transplant, Cardio-Oncology and Cardio-Genetics with an additional 300 patients in a robust multi-disciplinary muscular dystrophy clinic. Both our transplant and VAD programs have grown significantly in recent years, and with new partnerships within our ACHD program, the largest in the country, continued expansion is anticipated. Our Heart Center is vigorously engaged in family centered care and quality improvement initiatives focused on the institutional pillars of Treat Me Well, Navigate My Care, Do Not Harm Me, Heal Me, and Treat Me with Respect.

Nationwide Children’s Hospital is the primary pediatric teaching facility for The Ohio State University in Columbus Ohio. THC embraces a culture of patient safety and quality, transparency, engagement in translational/outcomes research, excellence in education, value-based care and public health awareness. This creates ample opportunities for professional growth and leadership for the candidate. Other clinical responsibilities will include out-patient clinics (specialized and potentially some general) during off-service time and general cardiology night/weekend call. THC’s comprehensive services include a single ventricle program, neurodevelopmental and cardiogenetic services, thoracic organ transplantation program, fetal cardiac intervention, blood conservation strategies, as well as an extensive outreach network. Annual clinical metrics for THC include: 400 cardiothoracic surgeries, 700-800 cardiac interventional and EP procedures, and ~20,000 cardiology out-patient encounters. We have a robust pediatric cardiology fellowship with advanced training opportunities in ACHD, interventional catheterization, and non-invasive imaging along with master’s programs. We participate in numerous multicenter clinical trials and quality initiatives including STS, PC4, PAC3, IMPACT, NPC-QIC and CNOC as well as heart failure and transplant-specific collaboratives (PHTS and the ACTION network). We are directly linked to our Center for Cardiovascular Research Institute which has an NIH T-32 training grant.

Interested candidates are encouraged to submit their curriculum vitae to:

**Rob Gajarski**, MD, Cardiology Section Chief and Transplant Director  
[Robert.gajarski@nationwidechildrens.org](mailto:Robert.gajarski@nationwidechildrens.org)

count this year. More than 40 new cardiac device specialists were added to the Geneva team.

- Specialty Expansion for Children with Cardiac Devices – GHS has also boosted its impact in pediatric cardiac care through contracts with Nemours Health's Dupont Hospital for Children and Pediatric Cardiology Center of Oregon to help monitor children with cardiac devices.

[www.genevahealthsolutions.com](http://www.genevahealthsolutions.com)

### Texas Children's Hospital Again Ranks Among the Best Children's Hospitals Nationally by US News & World Report

*Texas Children's Heart Center and Pulmonology Rank 1<sup>st</sup> Nationwide*

Texas Children's Hospital is proud to consistently be recognized as a leader in pediatric care by U.S. News & World Report, tying for third overall in their 13th annual Best Children's Hospitals rankings. Again, Texas Children's is named as the best place in the country for children in need of both pediatric cardiology and heart surgery, as well as pulmonary care. Additionally, six of the



*Texas Children's Heart Center and Pulmonology is ranked 1<sup>st</sup> nationwide.*

hospital's subspecialties rank in the top three and all rank within the top 10.

For more than a decade, no other pediatric hospital in the state ever achieved an overall ranking as high as Texas Children's. For more information, visit [texaschildrens.org/best](http://texaschildrens.org/best).

*Ranked Among the Top 10 in All Subspecialties*

In addition to ranking pediatric hospitals overall, US News also ranks the top 50 pediatric hospitals across 10 major subspecialties each year. Texas Children's is one of only 10 children's hospitals across the country to achieve the Honor Roll designation, and the only hospital in the state of Texas awarded this distinction.

With the partnership of academic affiliate Baylor College of Medicine, Texas Children's is a distinguished leader and resource for health and hope to children and their families. The hospital earns the U.S. News Honor Roll distinction by ranking as one of America's best in:

- #1 Cardiology and heart surgery
- #1 Pulmonology
- #2 Gastroenterology and GI surgery
- #2 Nephrology (kidney disorders)
- #3 Cancer
- #3 Neurology and neurosurgery
- #6 Urology
- #7 Neonatology (tied for 7)
- #8 Diabetes and endocrinology
- #10 Orthopedics

*Global Leader in Pediatric Heart Care*

For more than 60 years, the integrated, multidisciplinary team at Texas Children's Heart Center has combined cutting-edge technology with a compassionate and family-centered approach to care. Annually, nearly 1,000 surgeries and more than 1,300 cardiac catheterization procedures are performed in the new, state-of-the-art Lester and Sue Smith Legacy Tower, the home of Texas Children's Heart Center, where a team-based approach brings experts in every aspect of cardiac care to the bedside.

Texas Children's Heart Center cardiologists, congenital heart surgeons,



### Noninvasive Cardiac Imaging Specialist

The Heart Center at Nationwide Children's Hospital (NCH) seeks a Noninvasive Cardiac Imaging specialist at the assistant or associate professorial level. Candidates must be board-certified in pediatric cardiology and advanced imaging training is required. A research focus is expected. Candidates with expertise in fetal cardiology are preferred. The successful candidate will join our IAC-accredited Noninvasive Cardiac Imaging team which performs >16,000 echocardiographic studies annually. Our fetal cardiology program continues to grow programmatically, in clinical volume, outreach, and a recently developed a Fetal Cardiac Intervention program. We have treated international and local fetal patients with HLHS, critical aortic stenosis, and pulmonary atresia. There is also an active fetal sheep research program. The successful candidate will be well supported to excel in both clinical and research endeavors. Our program includes a 4th year Advanced Noninvasive Cardiac Imaging fellowship to complement the core pediatric and adult congenital cardiology fellowship programs.

The Heart Center embraces a culture of patient safety and quality, transparency, value-based care, public health awareness, excellence in education and engagement in translational/outcomes research. The Heart Center has numerous regional partnerships including the Congenital Heart Collaborative which provides additional opportunity for collaborative research. Our program is integrated with the Center for Cardiovascular Research providing infrastructure to support the clinical research enterprise. Nationwide Children's Hospital is a 464 bed stand-alone children's hospital and is the pediatric teaching facility for The Ohio State University School of Medicine. Columbus is the state capital and the 14th most populous city in the US (metropolitan population just over 2 million). It is a diverse community with excellent schools, a thriving economy, and a vibrant arts/food scene.

Candidates may submit their curriculum vitae by email to:

**John Kovalchin, MD**  
Director of Echocardiography  
[John.Kovalchin@nationwidechildrens.org](mailto:John.Kovalchin@nationwidechildrens.org)

**Robert Gajarski, MD**  
Cardiology Section Chief  
[Robert.Gajarski@nationwidechildrens.org](mailto:Robert.Gajarski@nationwidechildrens.org)

cardiac anesthetists and cardiac intensivists are world-renowned leaders in the field and work together to treat some of the rarest and most complex heart cases from Houston, across Texas, the U.S. and around the world. The multidisciplinary team strives to provide unparalleled care at every point from diagnosis through treatment and follow-up, in order to achieve the best possible care for each patient.

Areas of special expertise of the Heart Center include: cardiac catheterization, congenital heart surgery, electrophysiology, adult congenital heart disease, cardiac nursing, cardiac critical care, coronary artery anomalies, pulmonary vein stenosis, Marfan syndrome and connective tissue disorders, and one of the largest cardiac transplant and ventricular assist device programs in the world.

*The Destination for Children with Lung Disease*

Offering services to treat children dealing with any breathing problem, Texas Children's pulmonary team manages a wide range of common and rare pediatric lung disorders. With more than 16,000 outpatient visits annually, the hospital has numerous specialty clinics focused on severe asthma, cystic fibrosis, pulmonary hypertension, lung transplant clinic, tracheostomy and ventilator, aerodigestive multispecialty clinics, sleep disorders, and more.

The hospital's pulmonary team offers a wide array of specialized programs. Texas Children's Cystic Fibrosis (CF) Care Center is the only accredited pediatric CF center in Southeast Texas. Its Pulmonary Hypertension Program is one of the few programs in the U.S. dedicated to treating children; because of this, Texas Children's has extensive experience in the diagnosis and treatment of infants, children and teens with this rare condition. Additionally, Texas Children's has one of the largest and most successful pediatric lung transplant programs in the world and is one of only two institutions worldwide that performs an average of 10 pediatric lung transplants each year. With a typical wait time of four to six months for new lungs, Texas Children's transplants children from all areas of the United States. As a result of these programs and others, Texas Children's is also one of the largest training programs of future pediatric lung specialists.

[www.health.usnews.com/best-hospitals/pediatric-rankings](http://www.health.usnews.com/best-hospitals/pediatric-rankings)



LOVE where you work.  
Live where you LOVE.



### Pediatric Electrophysiologist Opportunity DENVER, COLORADO

If you are experienced in invasive and general pediatric cardiology and love fresh air, mountain views and outdoor activities, this opportunity is for you!

**Develop and build the new pediatric EP service line at Rocky Mountain Hospital for Children (RMHC)**, an affiliate of HCA's HealthONE system, the largest hospital system in the Denver metro area. We offer a competitive salary, comprehensive benefits and a 2-year income support package for program ramp-up provided by RMHC.

**Rocky Mountain Pediatric Cardiology** is a five-physician practice. We provide inpatient and outpatient services at RMHC, and in offices and outreach clinics across metro Denver and neighboring states.

**Rocky Mountain Hospital for Children** at Presbyterian/St. Luke's Medical Center offers all the advantages of a large specialty medical center with the specialized services of a children's hospital. RMHC is the region's only hospital with a Level IV Maternal Care Program and Level IV Neonatal Intensive Care Unit.

For more information:  
[mednax.com/careers](http://mednax.com/careers)

Contact:  
**Janet Friedman, Clinical Recruiter**  
[janet\\_friedman@mednax.com](mailto:janet_friedman@mednax.com)  
800-243-3839, ext. 5589

**Rocky Mountain Pediatric Cardiology**  
an affiliate of **MEDNAX**

MEDNAX is an Equal Opportunity Employer



## Pediatric Electrophysiologist

The Heart Center at Nationwide Children's Hospital in conjunction with The Ohio State University Department of Pediatrics in Columbus, Ohio seeks a board-certified/eligible, academic physician at any professorial level with advanced training in electrophysiology to join our team of two full-time electrophysiologists, two advance practice nurses and two EP nurses. Additionally, the successful candidate will participate in a limited amount of general pediatric cardiology that includes night call and in-patient consult service.

The Heart Center is a dedicated hospital service-line that carries the mission of providing state-of-the-art, cost-effective care to our patients with congenital and acquired heart disease regardless of age. The Heart Center has >18,000 out-patient encounters per year including multiple specialty clinics (e.g. Fontan, muscular dystrophy, preventive care, cardiogenetic). The in-patient medical discharges average 1300/yr including ~400 annual surgeries. The Heart Center has 37 cardiologists and four cardiothoracic surgeons, a dedicated 20-bed CTICU and 24-bed cardiac stepdown unit, and a dedicated administration team. Excellent services in cardiac intensive and stepdown care, catheterization and intervention, non-invasive imaging, electrophysiology, heart failure and heart/heart-lung/lung transplantation are on-site. The Heart Center has a robust adult congenital heart service. The population served includes the regional population, a large number of referred cases for advanced intervention and surgery, an extensive state-wide outpatient network (pediatric and adult congenital) and patients managed with regional partners including the newly formed Congenital Heart Collaborative.

Our program is integrated with the Center for Cardiovascular Research as well as the Center for Genomic Research. Nationwide Children's Hospital is a 464 bed stand-alone children's hospital and is the pediatric teaching facility for The Ohio State University School of Medicine. Columbus is the state capital and the 14th most populous city in the US (metropolitan population just over 2 million). It is a diverse community with excellent schools, a thriving economy and a vibrant arts/food scene.

Candidates are encouraged to submit their curriculum vitae by email to:

**Naomi Kertesz, MD**  
 Director of Electrophysiology and Pacing  
[Naomi.Kertesz@nationwidechildrens.org](mailto:Naomi.Kertesz@nationwidechildrens.org)

*The Ohio State University is an Equal Opportunity, Affirmative Action Employer. Women, minorities, veterans, and individuals with disabilities are encouraged to apply.*



Subscribe Electronically to CCT

Free on the Home Page

[www.CongenitalCardiologyToday.com](http://www.CongenitalCardiologyToday.com)



Recruit with CCT

Recruitment Advertisements are Listed

- In print and electronic monthly issue
- On CCT's website
- In CCT's monthly email blast

Contact: [Kate@cct.bz](mailto:Kate@cct.bz)



**CONGENITAL  
 CARDIOLOGY  
 TODAY**

**Founder &  
 Senior Editor**

Tony Carlson  
[Tony@cct.bz](mailto:Tony@cct.bz)

**Editor-in-Chief**

Kate Baldwin  
[Kate@cct.bz](mailto:Kate@cct.bz)

**Co-Founder &  
 Medical Editor**

John W. Moore, MD, MPH  
[Dr.John@cct.bz](mailto:Dr.John@cct.bz)

**Editor-in-Chief  
 Emeritus**

Richard Koullanis

**Staff  
 Editor**

Lorraine Watts

**Staff Editor &  
 Writer**

Virginia Dematatis

**Editorial Board**

Teiji Akagi, MD	Gerald Ross Marx, MD
Zohair Al Halees, MD	Tarek S. Momenah, MBBS, DCH
Mazeni Alwi, MD	Toshio Nakanishi, MD, PhD
Felix Berger, MD	Carlos A. C. Pedra, MD
Fadi Bitar, MD	Daniel Penny, MD, PhD
Jacek Bialkowski, MD	James C. Perry, MD
Mario Carminati, MD	Shakeel A. Qureshi, MD
Anthony C. Chang, MD, MBA	P. Syamasundar Rao, MD
John P. Cheatham, MD	Andrew Redington, MD
Bharat Dalvi, MD, MBBS, DM	Carlos E. Ruiz, MD, PhD
Horacio Faella, MD	Girish S. Shirali, MD
Yun-Ching Fu, MD	Horst Sievert, MD
Felipe Heusser, MD	Hideshi Tomita, MD
Ziyad M. Hijazi, MD, MPH	Gil Wernovsky, MD
Ralf Holzer, MD	Zhuoming Xu, MD, PhD
Marshall Jacobs, MD	William C. L. Yip, MD
R. Krishna Kumar, MD, DM, MBBS	Carlos Zabal, MD
John Lamberti, MD	

© 2019 by Congenital Cardiology Today  
 ISSN 1554-7787 print - ISSN 1554-0499 electronic  
 Published monthly. All rights reserved.

*Statements or opinions expressed in Congenital Cardiology Today reflect the views of the authors and sponsors, and are not necessarily the views of Congenital Cardiology Today.*

Official Publication of the CHIP Network

**CHIP NETWORK**  
 CONGENITAL HEART INTERNATIONAL PROFESSIONALS


The congenital heart professionals network exists to facilitate communications between congenital heart professionals locally, regionally, and globally.

JOIN TODAY

[www.chip-network.org](http://www.chip-network.org)



Funded by Cincinnati Children's Heart Institute



Repositionable and Retrievable  
 Prior to Release

Tight and Compact Windings  
 Ensure Efficient Occlusion

Designed to Match Individual  
 Morphologies and Sizes

# NIT-OCCLUD<sup>®</sup> Coil System

for PDA Closure

## Designed For the Safe and Atraumatic Occlusion of the Congenital Heart Defect PDA (Patent Ductus Arteriosus)

**INDICATIONS FOR USE:**

The Nit-Occlud<sup>®</sup> PDA coil is a permanently implanted prosthesis indicated for percutaneous, transcatheter closure of small to moderate size patent ductus arteriosus with a minimum angiographic diameter less than 4mm.

**NIT-OCCLUD BRIEF STATEMENT:**

Do not implant the Nit-Occlud PDA into patients who have endocarditis, endarteritis, active infection, pulmonary hypertension (calculated PVR greater than 5 Wood Units), thrombus in a blood vessel through which access to the PDA must be obtained, thrombus in the vicinity of the implantation site at the time of the implantation or patients with a body weight < 11 lbs. (5kg). An angiogram must be performed prior to implantation for measuring length and diameter of the PDA. Only the pfm medical implantation delivery catheter should be used to implant the device. Administration of 50 units of heparin per kg bodyweight should be injected after femoral sheaths are placed. Antibiotics should be given before (1 dose) and after implantation (2 doses) to prevent infection during the implant procedure. Do not implant the Nit-Occlud PDA in an MR environment. Do not pull the Nit-Occlud coil through heart valves or ventricular chambers. Contrast media should not be injected through the implantation catheter. The catheter must not be connected to high pressure injectors. Patients may have an allergic response to this device due to small amounts of nickel that has been shown to be released from the device in very small amounts. If the patient experiences allergic symptoms, such as difficulty in breathing or swelling of the face or throat, he/she should be instructed to seek medical assistance immediately. Antibiotic prophylaxis should be performed to prevent infective endocarditis during first 6 months after coil implantation. Potential Adverse Events: Air embolism, Allergic reaction to drug/contrast, Apnea, Arrhythmia requiring medical treatment or pacing, Arteriovenous fistula, Bacterial endocarditis, Blood loss requiring transfusion, Chest pain, Damage to the tricuspid or pulmonary valves, Death, Embolization of the occluder, requiring percutaneous or surgical intervention, Endarteritis, False aneurysm of the femoral artery, Fever, Headache/ Migraine, Heart failure, Hemolysis after implantation of the occluder, Hypertension, Hypotension or shock, Infection, Myocardial infarction, Occluder fracture or damage, Perforation of the heart or blood vessels, Stenosis of the left pulmonary artery or descending thoracic aorta, Stroke/TIA, Thromboembolism (cerebral or pulmonary), Valvular Regurgitation, Vessel damage at the site of groin puncture (loss of pulse, hematoma etc.).

Nit-Occlud is a registered trademark of pfm medical Inc.

Rx only CV9064 - 5/17 ©2017 B. Braun Interventional Systems Inc.

Distributed by:

B. Braun Interventional Systems Inc.

824 Twelfth Avenue | Bethlehem, PA 18018 | USA

Tel 877 836 2228 | Fax 610 849 1334 | www.bisusa.org

